# Comparison of the Efficacy and Safety of Venetoclax in Combination With 3 Days Decitabine (DEC3-VEN) vs. Venetoclax in Combination With Azacitidine (VIALE-A) in the Treatment of Elderly Patients or Unfit, New-diagnosis Acute Myeloid Leukemia Patients

> **NCT06073730** · PHASE3 · UNKNOWN · sponsor: **The Second Affiliated Hospital of Kunming Medical University** · enrollment: 154 (estimated)

## Conditions studied

- Elderly AML Patients
- Unfit, New-diagnosis AML
- Acute Myeloid Leukemia
- Venetoclax
- Decitabine

## Interventions

- **PROCEDURE:** Experimental: Venetoclax in combination with Decitabine (+-sorafenib)
- **PROCEDURE:** Active Comparator: Standard dose of Venetoclax + Azacitidine

## Key facts

- **NCT ID:** NCT06073730
- **Lead sponsor:** The Second Affiliated Hospital of Kunming Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-11-01
- **Primary completion:** 2024-11-01
- **Final completion:** 2025-11-01
- **Target enrollment:** 154 (ESTIMATED)
- **Last updated:** 2023-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06073730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06073730, "Comparison of the Efficacy and Safety of Venetoclax in Combination With 3 Days Decitabine (DEC3-VEN) vs. Venetoclax in Combination With Azacitidine (VIALE-A) in the Treatment of Elderly Patients or Unfit, New-diagnosis Acute Myeloid Leukemia Patients". Retrieved via MORVS 2026-11-02 from https://api.morvs.ai/clinical/NCT06073730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*